Loading...
ENDP.Q logo

Endo, Inc.OTCPK:ENDP.Q Rapport sur les actions

Capitalisation boursière US$141.1k
Prix de l'action
n/a
US$16.66
n/ddécote intrinsèque
1Y-98.9%
7D0%
1D
Valeur du portefeuille
​
Voir

Endo, Inc.

OTCPK:ENDP.Q Rapport sur les actions

Capitalisation boursière : US$141.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Endo International (ENDP.Q) Aperçu de l'action

A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. Plus de détails

ENDP.Q analyse fondamentale
Score flocon de neige
Évaluation4/6
Croissance future0/6
Performances passées0/6
Santé financière2/6
Dividendes0/6

Récompenses

Se négocie à 100% en dessous de notre estimation de sa juste valeur

Analyse des risques

Cours de l'action très volatil au cours des 3 derniers mois par rapport au marché US

Capitaux propres négatifs

Les revenus ont diminué de 41.7% par an au cours des 5 dernières années

N'a pas de capitalisation boursière significative ( $141K )


ENDP.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Endo International plc Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Endo International
Historique des cours de bourse
Prix actuel de l'actionUS$0.0006
Plus haut sur 52 semainesUS$0.08
Plus bas sur 52 semainesUS$0.000001
Bêta0.80
Variation sur 1 mois50.00%
Variation sur 3 mois0%
Variation sur 1 an-98.91%
Variation sur 3 ans-99.99%
Variation sur 5 ans-99.99%
Évolution depuis l'introduction en bourse-100.00%

Nouvelles et mises à jour récentes

Recent updates

Seeking Alpha • Aug 16

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Endo International (NASDAQ:ENDP) creditors are looking at putting the pharma company up for sale through a bankruptcy, likely through a Chapter 11 filing in New York, Bloomberg reported. Endo (ENDP) has a debt load of more than $8B and is still facing many lawsuits over its alleged role in the nation's opioid epidemic. A bankruptcy filing would make it easier for Endo (ENDP) to make deals with with governments and other entities suing the company. Bloomberg said that some first-lien lenders are competing to use their debt holdings toward a bid for the company’s assets. Seeking Alpha contributor CashFlow Hunter, which has a strong sell rating on Endo (ENDP), has said a bankruptcy filing is imminent.
Seeking Alpha • Aug 03

Endo International sees 23% rise on 3x higher than normal volume

Shares of Endo International (NASDAQ:ENDP) have risen sharply and are up 23% Wednesday afternoon amid three times higher than usual daily volume. The drugmaker's average daily volume is ~46.2M shares. As of 215p ET, more than 138M shares had traded hands. Endo (ENDP) is also having unusual options trading volume that is six times the daily normal. Seeking Alpha contributor CashFlow Hunter says the company is a strong sell with a bankruptcy filing likely.
Seeking Alpha • Jul 25

Endo outperforms defying bankruptcy fears and generic entry

The shares of Endo International (NASDAQ:ENDP) rose sharply on Monday even as the company continues to grapple with concerns over the generic threat to a key drug, failure to fulfill debt commitments, and potential bankruptcy filing amid ongoing opioid litigation. Despite an ~89% YTD decline, Endo (ENDP) has added ~13% over the past 30 days outperforming the broader market, as shown in this graph. The upsurge comes despite a recent WSJ report on the company’s plan to file for Chapter 11 bankruptcy without striking a settlement on thousands of opioid claims. In June, Dublin, Ireland-based Endo (ENDP) opted to skip interest payments owed to its junior bondholders citing the ongoing talks with certain creditors regarding its decision to evaluate strategic alternatives. A decline in earnings, driven in part by the loss of exclusivity for its leading sales generator, Vasostrict, has exacerbated the operational issues. In May, Piper Sandler downgraded Endo (ENDP), noting the generic competition to the vasopressin injection, which added $155.9M to the company topline in 1Q 2022 with ~30% YoY decline.
Seeking Alpha • Jul 12

Endo weighs bankruptcy filing without opioid settlement - WSJ

Endo International (NASDAQ:ENDP) shares plunged ~20% Tuesday after The Wall Street Journal reported that the generic drugmaker is advancing towards a bankruptcy filing without reaching a settlement on opioid claims against the company. According to people familiar with the matter, despite years of negotiations with opioid claimants, Endo (ENDP) is weighing chapter 11 bankruptcy to restructure its over $8B debt and thousands of ongoing litigations. Endo (ENDP) has been negotiating with a group of senior creditors after the company missed interest payments to junior bondholders last month, the people said, adding that the management expects to reach a deal with them before a near-term bankruptcy process starts. However, a bankruptcy filing is unlikely if the company inks agreements with junior bondholders and opioid plaintiffs, the people said, noting that the situation could change. Endo (ENDP) declined to comment. Read: “Bankruptcy filing should be imminent” for Endo (ENDP), Seeking Alpha contributor CashFlow Hunter predicted in May.
Seeking Alpha • Jun 29

Endo International cools off, giving back some of its 85% Tuesday gain

Shares of Endo International are down 24% in Wednesday afternoon trading, a day after the pharma closed up 85%. The reason for Tuesday's surge was a news release issued by law firm White & Case on behalf of a group of institutional investors holding unsecured notes in Endo (NASDAQ:ENDP) subsidiaries. The group has proposed that the company commence a cash tender offer or commence a debt-for-debt exchange. Also, it is against a near-term bankruptcy filing as Endo (ENDP) has strong liquidity and it "could destroy significant value for stakeholders." Endo (ENDP) has been struggling as a result of multi-million-dollar settlements in state opioid crisis cases.
Seeking Alpha • May 10

Endo: Stick A Fork In It

Second quarter guidance implies catastrophic sales and margins from Vasostrict. Bonds plummeted implying first lien debt might be impaired. Possibly impairment of first lien debt and near certain impairment of second lien debt means zero equity value. Bankruptcy filing should be imminent.
Seeking Alpha • Mar 07

Endo: About As Bad As It Gets

Entrance of generic competitor to Vasostrict materially hurting revenue. QWO uptake seems slow with concerns around discoloration side-effect. Q1 guide implies leverage rising dangerous levels. Bankruptcy seems like an increasingly likely option.
Seeking Alpha • Dec 16

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Eagle Pharmaceuticals receives FDA approval to sell a generic form of vasopressin, a competitor to ENDP's Vasostrict. This approval follows Eagle's courtroom win in a patent dispute with Endo several months ago. Vasostrict is Endo's biggest revenue source, responsible for $786 million of high margin sales last year. Eagle expects 180-day marketing exclusivity for vasopressin. Continue to see the stock as high risk.
Seeking Alpha • Nov 02

Endo: A Win In California But Equity Value Still A Question

California State Court hands Endo and other opioid producers a temporary win in liability trial. Tentative ruling directs manufacturers to file a statement of decision within 30 days. Ruling likely takes away major liability in the country's biggest state at least for a while. Leverage remains too high, particularly with Vasostrict EBITDA at risk. Bankruptcy is now likely off the table but struggle to see equity value.
Seeking Alpha • Aug 31

Endo International: Loses Vasostrict Trial

Judge rules Eagle Pharmaceuticals' version of the drug does not infringe on two patents held by Par Pharmaceuticals, the unit that produces vasostrict. Expect Eagle to start producing and marketing a generic form of vasostrict to treat low blood pressure in the next few months. Approximately 30% of Endo Pharmaceuticals' revenue and EBITDA will take a hit. The loss likely wipes out any equity value for Endo and impairs unsecured bonds.
Seeking Alpha • Aug 20

Endo International: Hires Restructuring Advisor

The company is hiring Alvarez & Marsal, which specializes in bankruptcy restructuring. The move is somewhat surprising from a timing perspective. New York opioid and Vasostrict trials are still ongoing.
Seeking Alpha • Aug 07

Endo International: All About Ongoing Litigation

Company settled with the eastern TN counties for $35mm but do the economics make any sense? NY litigation is ongoing with plaintiffs seeking default liability judgment on the same grounds as TN. Vasostrict trial with Eagle Pharmaceuticals is ongoing. >25% of EBITDA at risk. Quarter operationally solid, but questions remain on market acceptance of QWO.
Seeking Alpha • Jul 15

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

The denied request is likely the last chance to stop the Tennessee damages trial set to begin on July 26. The company already has a default judgment against it. The company could face a $2.4 billion judgment leveled against it. Appeal denial is one more piece pointing to likely bankruptcy filing.
Seeking Alpha • Jun 30

Endo International: Bankruptcy Seems Like The Only Practical Option

A Tennessee state court issued a "default judgement" in April against the company in the lawsuit by county prosecutors over the company's generic for oxycontin, Opana. Earlier this month, a Tennessee appellate court declined to review that default judgement. The damages trial begins on July 26 in Tennessee. Plaintiffs are seeking $2.4 billion. A trial for a suit against the company begins in New York on June 28th and a California trial is ongoing. A bankruptcy filing is very likely the only way to settle all of these cases in a manner that preserves value.

Rendement pour les actionnaires

ENDP.QUS PharmaceuticalsUS Marché
7D0%4.9%1.0%
1Y-98.9%44.2%28.7%

Rendement vs Industrie: ENDP.Q a sous-performé le secteur US Pharmaceuticals qui a rapporté 44.2 % au cours de l'année écoulée.

Rendement vs marché: ENDP.Q a sous-performé le marché US qui a rapporté 28.7 % au cours de l'année écoulée.

Volatilité des prix

Is ENDP.Q's price volatile compared to industry and market?
ENDP.Q volatility
ENDP.Q Average Weekly Movement207.3%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Cours de l'action stable: Le cours de l'action de ENDP.Q a été volatil au cours des 3 derniers mois par rapport au marché US.

Volatilité au fil du temps: La volatilité hebdomadaire de ENDP.Q est passée de 125% à 207% au cours de l'année écoulée.

À propos de l'entreprise

FondéeSalariésPDGSite web
19972,931Blaise Colemanwww.endo.com

Endo International plc Résumé des fondamentaux

Comment les bénéfices et les revenus de Endo International se comparent-ils à sa capitalisation boursière ?
ENDP.Q statistiques fondamentales
Capitalisation boursièreUS$141.13k
Bénéfices(TTM)-US$2.45b
Recettes(TTM)US$2.01b
0.0x
Ratio P/S
0.0x
Ratio P/E

Le site ENDP.Q est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
ENDP.Q compte de résultat (TTM)
RecettesUS$2.01b
Coût des recettesUS$941.90m
Marge bruteUS$1.07b
Autres dépensesUS$3.52b
Les revenus-US$2.45b

Derniers bénéfices déclarés

Dec 31, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)-10.41
Marge brute53.17%
Marge bénéficiaire nette-121.69%
Ratio dettes/capitaux propres-123.5%

Quelles ont été les performances à long terme de ENDP.Q?

Voir les performances historiques et les comparaisons

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2024/05/02 14:06
Cours de l'action en fin de journée2024/05/02 00:00
Les revenus2023/12/31
Revenus annuels2023/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Endo, Inc. est couverte par 32 analystes. 0 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Richard SilverBarclays
Gary NachmanBMO Capital Markets Equity Research
Sumant Satchidanand KulkarniBofA Global Research